Suppr超能文献

在惰性 B 细胞非霍奇金淋巴瘤患者中进行低剂量 2×2Gy 重复放射治疗。

Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.

机构信息

Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

出版信息

Cancer Med. 2020 Jun;9(11):3725-3732. doi: 10.1002/cam4.2796. Epub 2020 Apr 6.

Abstract

PURPOSE

In patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL), one course of low-dose radiotherapy (LD-RT) 2 × 2 Gy is emerging as new option of therapy in palliative setting. Efficacy of LD-RT when repeated remains to be determinate. This study aims to assess the efficacy of repeated LD-RT given in patients with indolent B-NHL.

MATERIALS AND METHODS

All consecutive adult patients who received two or more courses of LD-RT 2 × 2 Gy for indolent B-NHL at Gustave Roussy institution, during the period 1990-2015 were retrospectively investigated.

RESULTS

Thirty-three patients received two or more courses of LD-RT for indolent B-NHL during the study period. The median age was 57 (range 37-80) years, histological types were distributed among follicular lymphoma (n = 24 pts; 73%), marginal-zone lymphoma (n = 6 pts; 18%), and primary cutaneous follicle center lymphoma (n = 3 pts; 9%). The median number of low-dose radiation therapy courses given per patients was 2 (range 2-6). The overall response rates following the first and the second course of LD-RT were 96% and 88%, respectively (P = .31). The 1- and 2-years local control rates following the first courses of LD-RT were 94% (CI 95: 86-100) and 94% (CI 95: 86-98); and were 91% (CI 95: 82-100) and 88% (CI 95: 77-100) following the second course of LD-RT (P = .39).

CONCLUSION

The repeated courses of LD-RT offered similar efficacy compare with the first course in patients with indolent B-NHL. LD-RT repeated is a simple, easy to give, and non-toxic asset that could be investigated as treatment option in patients with indolent B-NHL.

摘要

目的

在惰性 B 细胞非霍奇金淋巴瘤(B-NHL)患者中,低剂量放疗(LD-RT)2×2 Gy 作为一种新的姑息治疗选择正在出现。重复 LD-RT 的疗效仍有待确定。本研究旨在评估在惰性 B-NHL 患者中重复给予 LD-RT 的疗效。

材料和方法

回顾性调查了 1990 年至 2015 年期间在 Gustave Roussy 机构接受两次或两次以上 LD-RT 2×2 Gy 治疗的连续成年惰性 B-NHL 患者。

结果

在研究期间,33 名患者接受了两次或两次以上的 LD-RT 治疗。中位年龄为 57 岁(范围 37-80 岁),组织学类型分布为滤泡性淋巴瘤(n=24 例;73%)、边缘区淋巴瘤(n=6 例;18%)和原发性皮肤滤泡中心淋巴瘤(n=3 例;9%)。每位患者接受的低剂量放疗疗程中位数为 2(范围 2-6)。首次和第二次 LD-RT 后的总体缓解率分别为 96%和 88%(P=.31)。首次 LD-RT 后 1 年和 2 年的局部控制率分别为 94%(CI 95%:86-100)和 94%(CI 95%:86-98);第二次 LD-RT 后 1 年和 2 年的局部控制率分别为 91%(CI 95%:82-100)和 88%(CI 95%:77-100)(P=.39)。

结论

在惰性 B-NHL 患者中,重复 LD-RT 疗程与首次疗程疗效相当。重复 LD-RT 是一种简单、易于实施且无毒的治疗方法,可作为惰性 B-NHL 患者的治疗选择进行研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a95d/7286454/c902c65d2cf4/CAM4-9-3725-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验